Filing summary
Entity discrepancy: The request metadata names Larimar Therapeutics, Inc., but the supplied Form 10-Q is for Zafgen, Inc. Confirm the issuer before relying on this summary.
Business context and reporting period
This unaudited quarterly report covers the three and nine months ended September 30, 2016. Zafgen was a clinical-stage biopharmaceutical company developing MetAP2 inhibitors for metabolic diseases. Its lead candidate was ZGN-1061, then in Phase 1 testing; the company had no product revenue.
Financial results and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 in 2016 and 2015 | $0 in 2016 and 2015 |
| Operating expenses | $14.8 million in 2016; $19.7 million in 2015 | $47.8 million in 2016; $50.6 million in 2015 |
| Net loss | $14.7 million in 2016; $19.9 million in 2015 | $47.4 million in 2016; $51.1 million in 2015 |
| Net loss per share | $0.54 in 2016; $0.73 in 2015 | $1.74 in 2016; $1.92 in 2015 |
| Cash used in operations | Nine-month 2016: $43.3 million; nine-month 2015: $41.6 million |
All figures are in U.S. dollars. At September 30, 2016, cash and cash equivalents were $24.9 million and marketable securities were $113.8 million, totaling $138.7 million. Total assets were $142.7 million, current liabilities $11.3 million, and total liabilities $12.5 million. The balance sheet reported $3.1 million of current notes payable and $1.2 million of long-term notes payable, net of discount. The credit facility’s stated annual interest rate was 8.1%; management reported an effective annual rate of approximately 10.8%.
No operating margin is meaningful because the company had no revenue and incurred operating losses. Nine-month 2016 investing activities provided $34.5 million, largely reflecting net maturities and purchases of marketable securities; financing activities used $2.0 million. Cash and cash equivalents declined by $10.7 million during the period.
Changes versus the prior comparable period
- Third-quarter operating expenses fell $4.9 million year over year, and net loss narrowed by $5.2 million. Research and development expense fell $4.2 million, mainly as beloranib trials wound down; ZGN-1061 spending increased.
- For the first nine months, operating expenses declined $2.8 million and net loss narrowed $3.7 million. Lower beloranib and ZGN-839 spending more than offset increased unallocated R&D costs and higher general and administrative expense.
- Operating cash use increased $1.7 million year over year. The prior-year period included $130.0 million of net proceeds from a follow-on offering; there was no comparable offering in 2016.
- Cash, cash equivalents and marketable securities decreased from $175.1 million at December 31, 2015 to $138.7 million at September 30, 2016.
Outlook, risks and unusual items
- Management expected available cash, cash equivalents and marketable securities to fund operating and capital requirements for at least 18 months from September 30, 2016, while cautioning that assumptions could prove wrong and capital could be used sooner. Additional financing may be needed.
- The company said it was dosing healthy participants in the single-ascending-dose portion and obese participants in the multiple-ascending-dose portion of the ZGN-1061 Phase 1 trial in the Netherlands, and expected Phase 1 clinical data by the end of Q1 2017. This was forward-looking guidance, not a reported result.
- In July 2016, Zafgen refocused on ZGN-1061 and suspended beloranib development after the FDA placed its application on full clinical hold in December 2015 following an imbalance in thrombotic events. The company cited potentially improved preclinical safety characteristics for ZGN-1061 but warned that clinical safety and efficacy remained unproven.
- The company planned to reduce its workforce by approximately 34% by December 2016. It recorded $1.5 million of restructuring costs through September 30, including $1.4 million cash costs; $1.1 million remained accrued at period end. Management did not expect significant additional restructuring costs.
- ZGN-839 development was suspended in October 2016, after the reporting date, as resources were concentrated on ZGN-1061 and discovery work.
- A putative securities class action related to beloranib disclosures was dismissed with prejudice in August 2016; plaintiffs appealed, and filed their opening brief on October 26, 2016. The company said it could not estimate possible losses.
- Key risks included reliance on a single clinical-stage lead candidate, possible thrombotic or other safety findings, clinical and regulatory uncertainty, third-party trial and manufacturing dependence, financing needs, workforce-transition risks, competition and intellectual-property challenges.
Important facts for investors to verify
- Confirm the filing issuer: the supplied document identifies Zafgen, Inc., not Larimar Therapeutics, Inc.
- Check subsequent ZGN-1061 trial disclosures against the stated expectation for Phase 1 data by the end of Q1 2017, including safety and thrombosis-related findings.
- Assess whether the stated 18-month cash runway assumptions held, considering operating cash use, trial costs and future financing.
- Review the outcome of the securities-litigation appeal and any later updates to contingencies.
- Verify completion and costs of the planned workforce reduction, and whether concentrating resources on ZGN-1061 changed spending or development plans.